Systems Biology accelerates GPCR drug candidate design by mimicking drug actions in vitro and in vivo

Key Advantages

Full ligand range

Proprietary modeling

We build  our proprietary systems biology models with our own experimental data, so our models are adaptable to specific projects. 

Full ligand range

We model the entire ligand range for GPCRs – from peptides to antibodies to small molecules – and cover everything from full/partial agonists, antagonists to orthosteric and allosteric ligands. We perform all our assays using unlabeled ligands, thereby excluding labeling artefacts.

In Vivo
Speedometer

Better prediction of in vivo effects

By honing in on promising compounds in an early stage, you can get a sense of which drugs to pursue for in vivo testing,  leading to better outcomes, faster.

Faster hit-to-lead time

By combining traditional and computational
pharmacology to identify the most promising ligands, we can decrease hit-to-lead time by up to 75%.

Key Advantages

Proprietary modeling

We build our proprietary systems biology models with our own experimental data, so our models are adaptable to specific projects.

Full ligand range

Full ligand range

We model the entire ligand range for GPCRs – from peptides to antibodies to small molecules – and cover everything from full/partial agonists, antagonists to orthosteric and allosteric ligands. We perform all our assays using unlabeled ligands, thereby excluding labeling artefacts.

In Vivo

Better prediction of in vivo effects

By honing in on promising compounds in an early stage,  you can get a sense of which drugs to pursue for in vivo
testing,  leading to better outcomes, faster.

Speedometer

Faster hit-to-lead time

By combining traditional and computational  pharmacology to identify the most promising ligands,
we can decrease hit-to-lead time by up to 75%.

How It Works

We create an in-house data set with your test compounds on your target GPCR. We analyze these data with our custom-designed systems biology model to help you identify the most promising drug candidates.

GPRC and ligands Network

We are open to a range of collaborations, from pilot projects to long-term partnerships